118 results on '"Billin AN"'
Search Results
2. THU-215 Artificial intelligence-derived granular histological markers of fibrosis from hematoxylin and eosin-stained whole slide images associate with non-invasive tests of fibrosis and prognosis to cirrhosis in patients with metabolic dysfunction-associated steatohepatitis
3. TOP-264 Paired assessment of enhanced liver fibrosis (ELF) and fibrosis-4 (FIB-4) scores is associated with an elevated risk of liver-related clinical events in participants with advanced fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH)
4. FOCUSSED NOISE MONITORING 2013
5. Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist
6. Elevated JAG1-NOTCH Signaling is Associated with Fibrosis Stages in Patients with PSC
7. Utility of SomaSignalTM panels for drug response and monitoring disease progression in patients with advanced fibrosis due to non-alcoholic steatohepatitis
8. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC
9. Use of antidiabetic and lipid-lowering medications associated with lower scores of liver fibrosis biomarkers in non-alcoholic steatohepatitis (NASH) patients
10. Proteomic Analysis of IPF Patient Serum Using the Somascan® Platform Identifies Potential Biomarkers of Disease and Outcome
11. AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trials
12. Isolation of Skeletal Muscle Stem Cells for Phenotypic Screens for Modulators of Proliferation
13. Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate
14. ASSOCIATION BETWEEN ANTIBIOTIC USE AND INFLAMMATORY BOWEL DISEASE OUTCOMES
15. Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers
16. NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned
17. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis
18. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
19. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients
20. IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH
21. Machine learned histological fibrosis score empowers characterization of baseline gene signatures associated with fibrosis progression or regression in a NASH F3/F4 clinical trial
22. Associations between novel serum biomarkers chitinase-2-like protein (YKL-40), type IV collagen, and thrombospondin-2 (TSP-2) with fibrosis stage and clinical outcomes in patients with primary sclerosing cholangitis (PSC)
23. Machine learning encoding of liver biopsy images enables prediction of molecular measurements in a NASH F3/F4 fibrosis clinical cohort
24. Machine learning-enabled continuous scoring of histologic features facilitates prediction of clinical disease progression in patients with non-alcoholic steatohepatitis
25. Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD
26. Multi stain graph fusion for multimodal integration in pathology
27. Semi‐Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA
28. Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors
29. A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis
30. The simultaneous removal of arsenic and manganese at a gold mine in Nevada
31. 20-day design build to save $50 million worth of equipment
32. Single process arsenic and antimony removal using coagulation and microfiltration
33. The pharmacokinetics, pharmacodynamics, and short-term safety of cilofexor, a nonsteroidal farnesoid X receptor agonist, in subjects with hepatic impairment
34. Serum bile acid species are associated with liver fibrosis and clinical disease progression in patients with primary sclerosing cholangitis
35. Phenome-wide association study of the FIB-4 index in a large, populational-based study in the United States
36. Hepatic transcriptomic analysis identifies a mast cell gene expression signature that correlates with fibrosis stage and is prognostic in patients with primary sclerosing cholangitis
37. Glympse liver test for noninvasive monitoring of combination drug therapy in a rat model of non-alcoholic steatohepatitis (NASH)
38. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
39. Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
40. Tu1618 – Patients with Functional Gastrointestinal Disorders (FGIDS) Benefit from a Multidisciplinary Integrated Treatment Approach to Reduce Anxiety and Depressive Symptoms
41. 273 – A Multidisciplinary Integrated Treatment Approach is Superior to Standard Care for Functional Gastrointestinal Disorders (FGIDS): A Case-Control Study
42. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
43. Correction to: HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction induced injury
44. HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury
45. Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement
46. The AMPK/p27Kip1 Axis Regulates Autophagy/Apoptosis Decisions in Aged Skeletal Muscle Stem Cells
47. Evaluation of SOMAscan as a discovery platform to identify noninvasive protein biomarkers for diagnosis and monitoring of NASH
48. The association of circulating microRNAs (miRs) with liver fibrosis stage and the impact of selonsertib treatment in patients with NASH
49. Abstract 4082: Time- and exposure-dependent pharmacodynamic changes induced by the BTK inhibitor GS-4059 in healthy subjects
50. Abstract 4016: Homogeneous BTK occupancy assay for pharmacodynamic assessment of GS-4059 target engagement
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.